Objective: Vascular access dysfunction is a major problem in hemodialysis patients. Only 50% of arteriovenous grafts (AVGs) will remain patent 1 year after surgery. AVGs frequently develop stenoses and occlusions at the venous anastomoses in the venous outflow tract. Lumen diameter is not only determined by intimal thickening but is also influenced by remodeling of the vessel wall. Vascular remodeling requires degradation and reorganization of the extracellular matrix by the degradation enzymes, matrix metalloproteinases (MMPs). In this study, we aimed to provide further insight into the mechanism of endothelial regulation of vascular remodeling and luminal narrowing in AVGs. Methods: End-to-side carotid artery-jugular vein polytetrafluoroethylene grafts were created in 20 domestic swine. The anastomoses and outflow vein were treated with Gelfoam matrices (Pfizer, New York, NY) containing allogeneic porcine aortic endothelial (PAE, n ‫؍‬ 10) cells or control matrices without cells (n ‫؍‬ 10), and the biologic responses to PAE implants were investigated 3 and 28 days postoperatively. Angiograms before euthanasia were compared with baseline angiograms. Tissue sections were stained with hematoxylin and eosin, Verhoeff elastin, and antibodies specific to MMP-9 and MMP-2 and underwent histopathologic, morphometric and immunohistochemical analysis. Results: Veins treated with PAE cell implants had a 2.8-fold increase in venous lumen diameter compared with baseline (P < .05), a 2.3-fold increase in lumen diameter compared with control, and an 81% decrease in stenosis (P < .05) compared with control at 28 days. The increase in lumen diameter by angiographic analysis correlated with morphometric analysis of tissue sections. PAE implants increased the venous lumen area 2.3-fold (P < .05), decreased venous luminal occlusion 66%, and increased positive venous remodeling 1.9-fold (P < .05) compared with control at 28 days. PAE cell implants reduced MMP-2 expression and neovascularization at 3 and 28 days and adventitial fibrosis at 28 days, suggesting a role of the implants in controlling the affects of medial and adventitial cells in the response to vascular injury. Conclusions: These results demonstrate that the adventitial application of endothelial implants significantly reduced MMP-2 expression within the venous wall, and increased venous lumen diameter and positive remodeling in a porcine arteriovenous graft model. Adventitial endothelial implants may be useful in decreasing luminal narrowing in a clinical setting. ( J Vasc Surg 2007;46:548-56.)
Luminal loss due to the formation of intimal hyperplasia has been attributed to smooth muscle cell (SMC) migration from the media into the intima combined with platelet and leukocyte activation and subsequent extracellular matrix deposition at the lumen side. It has recently become evident, however, that adventitial thickening, fibrosis, inflammation, and neovascularization also contribute to lesion formation, negative remodeling, and lumen loss after experimental vascular injury. [7] [8] [9] [10] In this paradigm, vascular injury elicits a cascade that begins with the proliferation of adventitial fibroblasts, their differentiation into myofibroblasts, secretion and activation of matrix metalloproteinases (MMPs), and cell migration from the adventitia and media to the intima. The adventitia is therefore a potential therapeutic target for AVG failure. Placement of allogeneic endothelial implants onto the adventitial surfaces of injured vessels effectively diminished intimal thickening after angioplasty and the creation of arteriovenous fistulas. [11] [12] [13] In the present study, we investigated the vascular responses to injury at the lumen, media, and adventitia of AVGs treated with perivascular allogeneic endothelial implants. We hypothesized that placement of endothelial implants, which have been shown to produce normal endothelial inhibitory compounds in vitro, onto the adventitia of venous anastomotic and outflow sites could increase positive or expansive venous remodeling and decrease luminal narrowing. We now report that the application of endothelial implants to the adventitia of AVGs significantly reduced angiographic vascular stenoses and increased histologic measures of venous lumen and total vessel areas 28 days after surgery. Furthermore, endothelial implants also reduced MMP-2 expression, adventitial fibrosis, and neovascularization compared with control.
METHODS

Formulation and testing of endothelial implants.
Porcine aortic endothelial (PAE) cells (Cell Applications, San Diego, Calif) were cultured and maintained in Gelfoam matrices (Pfizer, New York, NY) as previously described. 11 Sterile Gelfoam blocks (4.0 ϫ 1.0 ϫ 0.3 cm 3 ) were seeded with 1.25 to 1.66 ϫ 10 5 cells/cm 3 and incubated for about 2 weeks until confluent in Endothelial Basal Media (Lonza, Portsmouth, NH) supplemented with 5% fetal bovine serum (FBS) and 50 g/mL gentamicin. Confluence was determined by periodic evaluation of cell number after enzymatic digestion. 11 PAE cells were implanted after confluence was achieved. The production of heparan sulfate (HS), transforming growth factor-␤ 1 (TGF-␤ 1 ), nitric oxide (NO), and tissue inhibitors of metalloproteinases 1 and 2 (TIMP-1 and TIMP-2) by PAE cells cultured in Gelfoam matrices were used as markers of cell function. HS levels in conditioned media were determined using a dimethylmethylene blue binding assay. Concentrations of TGF-␤ 1 , TIMP-1, and TIMP-2 were determined by enzymelinked immunosorbent assay (ELISA; R&D Systems, Minneapolis, Minn). Total NO levels were determined indirectly in an ELISA assay (R&D Systems) based on the Greiss reaction. Control Gelfoam matrices that did not contain cells were incubated for up to 2 weeks in medium containing 5% FBS before implantation.
Placement of arteriovenous grafts. The ability of the endothelial implants to reduce stenosis and lumen loss when wrapped around AVGs was assessed in an established porcine AVG model. 14 The study used 20 male and female domestic Yorkshire pigs weighing 34 kg Ϯ 0.9 kg and 10 to 12 weeks of age (Wesley Looper Farm, Hickory, NC). The pigs received 650 mg aspirin 48 and 24 hours before surgery and 325 mg daily until the end of the study. All animals received intravenous (IV) dexamethasone (0.5 mg/kg) before surgery to minimize inflammation in the neck. Anesthesia was induced with Telazol (4.4 mg/kg; Wyeth, Madison, NJ), ketamine (2.2 mg/kg), glycopyrrolate (0.2 mg/mL), acepromazine maleate (10 mg/mL), and thiopental 2.5% (0.22 mL/kg). The pigs were intubated and anesthesia was maintained with isoflurane inhalant (0.5% to 2%) delivered through a volume-regulated ventilator. Intravenous heparin was administered before graft surgery as a 100 U/kg bolus. Additional bolus doses of heparin were administered as necessary to maintain an activated coagulation time (ACT) Ն200 seconds. All pigs received intramuscular buprenorphine (0.03 mg/kg) immediately after surgery.
Bilateral 8-cm neck incisions were made over the sternocleidomastoid muscle on each side of the neck. A 6-mm internal diameter polytetrafluoroethylene graft (Atrium Medical Corp, Hudson, NH) with an average length of 18.6 Ϯ 0.9 cm was tunneled in a subcutaneous tract between the two incisions. Oblique end-to-side anastomoses were made between the jugular vein and graft and the carotid artery and graft using 6-0 Prolene suture (Ethicon, Somerville, NJ).
After completion of the anastomoses, the graft was percutaneously cannulated just distal to the carotid arterygraft anastomosis. The venous anastomosis and outflow tract were imaged using 10 to 15 mL of full-strength Renografin (Bracco Diagnostics Inc, Princeton, NJ) and an OEC 9600 C-arm fluoroscope in two planes with 90°o ffsets. The anastomoses were then wrapped with two Gelfoam matrices containing PAE cells (n ϭ 10) or no cells (n ϭ 10), covering about 0.5 cm of graft and vessel equally (Fig 1) . Each proximal venous segment was also treated with one matrix containing PAE cells or no cells by placing the matrix longitudinally along the length of the vein, starting at the anastomotic site (Fig 1) , thereby covering an additional 3 to 4 cm of outflow vein.
Gelfoam is an approved gelatin-based surgical sponge that is commonly used in vascular access procedures as an adjunct to hemostasis. Gelfoam causes little cellular infiltra-tion and is generally left in place and the wound closed over it. Empty Gelfoam matrices were used as the control vehicle in this study.
Graft patency was confirmed weekly throughout the study by Doppler ultrasound imaging. Cine angiography was performed just prior to euthanasia as described above. Percent stenosis was calculated quantitatively for patent grafts by measuring the lumen diameter of the graft (LGD) distal to the arterial anastomosis and the lumen diameter at the venous anastomosis (LVD). Three measurements were made at each location and averaged. The percentage of stenosis was determined at implant (day 0) and at euthanasia (day 3 or 28) using the following equation: (LGD -LVD)/(LGD) ϫ 100.
Venous lumen diameter was determined by taking the average of 3 to 4 measurements starting just distal from the anastomotic site and along a 6-cm length of vein. The average venous lumen diameter (VLD) for each image was normalized by the corresponding LGD for that image. Late venous luminal gain (VLG) was determined by comparison of the venous lumen diameter after surgery (VLD day 0 ) to that just before euthanasia (VLD euth ). Luminal gain was calculated by dividing each venous diameter by the reference graft diameter (LGD) using the following equation: VLG ϭ (VLD euth /LGD euth ) -(VLD day 0 /LGD day 0 ). Data from orthogonal images were averaged so that each animal resulted in one data point for each analysis.
Tissue processing and staining. On postoperative days 3 and 28, animals were euthanized with IV sodium pentobarbital. The graft and associated vessels were perfusion fixed in situ with phosphate-buffered saline, followed by formalin. The anastomotic sites and surrounding tissue were trimmed, embedded in paraffin, sectioned, mounted on glass slides, and stained with hematoxylin and eosin (H&E). Three 5-m sections were obtained through each arterial anastomosis at 1-mm intervals and also across each venous anastomosis. After the last venous anastomotic section, five sections through the venous outflow tract at 2 to 3 mm intervals were obtained over an additional length of 15 mm of vein. Slides were read and interpreted by a board-certified veterinary pathologist blinded to treatment groups.
Histomorphologic findings were graded on a scale from 1 through 4, depending upon severity (0 ϭ no significant changes; 1 ϭ minimal; 2 ϭ mild; 3 ϭ moderate; 4 ϭ severe; Appendix Table, online only). Histomorphometric analysis was performed on Verhoeff stained sections from the arterial and venous sites of patent grafts from animals euthanized at 28 days. The intimal (I), medial (M) and lumen (L) areas were measured using computerized digital planimetry with an Olympus BX51 microscope, an Olympus DP-70 digital camera (Olympus Melville, NY), and customized software. The boundaries of each layer (lumen, intima and media) were outlined and the computer software determined the area (mm 2 ) within each outlined sector.
In anastomotic sections, which contained both vessel and graft, the vessel and graft were measured separately. Morphometric measurements were made by a boardcertified veterinary pathologist who was blinded to the treatment groups. The extent of luminal occlusion and intimal hyperplasia was determined by normalizing the intimal area by the lumen [I/(I ϩ L)] or media area [I/(I ϩ M)], respectively. Total vessel size and the extent of remodeling were assessed by measuring the area circumscribed by the outer border of the external elastic lamina of the vessel.
MMP expression was localized in venous sections by using antibodies specific for the precursor (pro) and activated forms of MMP-2 and MMP-9 (murine antihuman MMP-2 or rabbit antihuman MMP-9, 1:250 dilution, Chemicon International, Inc, Temecula, Calif). At least six nonoverlapping fields were analyzed per section for every specimen. For quantitative assessment of positive MMP staining, randomly selected areas were imaged using an Olympus BX60 microscope. Digital images were captured and analyzed using Image-Pro Plus 6.0 software (Media Cybernetics, Silver Spring, Md). Each area of interest was highlighted and positive staining quantified by color segmentation. The results were expressed as percentage of positive area (positive area in mm 2 over total area in mm 2 ). Quantitative assessment of positive staining was performed by an observer who was blinded to the treatment groups.
Statistical analysis. All data are presented as mean Ϯ standard error. Statistical analysis comparing treatment groups used a nonparametric Mann-Whitney test performed using GraphPad Prism 3.02 (GraphPad Software, San Diego, Calif). A Pearson correlation determined the relationship between lumen diameter and MMP expression. Values of P Ͻ .05 were considered significant.
RESULTS
Biologic effects of perivascular endothelial implants.
The number of PAE cells that could be recovered from Gelfoam matrices increased exponentially from 1.25 to 1.66 ϫ 10 5 cells/cm 3 on day 0 to 10 to 16 ϫ 10 5 cells/cm 3 at confluence. PAE cell/Gelfoam matrices were assayed for TGF-␤ 1 , TIMP-1, TIMP-2, NO, and HS production. Significant levels of HS (1.33 Ϯ 0.23 g/mL), TGF-␤ 1 (507 Ϯ 22 pg/mL), NO (2.1 Ϯ 0.40 mol/L), and TIMP-2 (9.3 Ϯ 0.96 ng/mL) per day were detected in conditioned media collected from postconfluent in vitro cohorts. These levels are similar to those produced from cells grown on tissue culture polystyrene (data not shown). TIMP-1 was not detected in conditioned media samples.
The pigs used in this study were randomly selected to receive Gelfoam with or without PAE cells (control). All incisions healed well and all animals gained weight throughout the respective postoperative period. Five animals in each group were euthanized at 3 and 28 days. Two control grafts and one PAE treated graft were occluded at euthanasia on day 3. One control and one treated graft were occluded at euthanasia on 28 day. All occlusions occurred early (Յ first 7 days) and were not unexpected in this model.
Analysis of angiograms of patent grafts obtained at baseline and euthanasia revealed an increase in VLG at day 28 for veins treated with PAE cells compared with control (1.8 Ϯ 0.58 vs 0.01 Ϯ 0.44, respectively). The treated veins increased 2.8-fold in diameter, from 1.04 Ϯ 0.09 at day 0 to 2.9 Ϯ 0.56 at day 28 (P Ͻ .05), and control veins remained essentially unchanged, from 1.28 Ϯ 0.13 at day 0 to 1.29 Ϯ 0.35 at day 28 (Fig 2) . Veins treated with PAE cell implants had a 2.3-fold increase in VLD compared with control, which appeared to extend over the 4-cm length covered by the implant and up to 2 cm beyond. No significant VLG was observed in control or animals treated with PAE cells at 3 days.
The cell-containing implants also reduced vein-graft stenosis by 81%, from 45% Ϯ 13% for control grafts to 8.5% Ϯ 2.9% for grafts treated with PAE cells (P Ͻ .05) at day 28. Morphometric analysis of the vein at the anastomotic and outflow sites (Table I) demonstrated similar results. Veins treated with cell-containing implants had a 2.3-fold increase in lumen area compared with control (P Ͻ .05). In addition, total vessel area increased from 11.16 Ϯ 1.97 mm 2 for control to 20.72 Ϯ 1.51 mm 2 for veins treated with PAE cells (P Ͻ .05), suggesting greater positive remodeling in the treated veins. PAE cells/Gelfoam also reduced venous luminal occlusion by 66% and intimal thickening by 51% (Table I) .
Morphometric analysis of graft sections at the venous anastomotic site revealed little differences in pseudointima (2.45 Ϯ 0.23 mm 2 and 2.23 Ϯ 0.14 mm 2 ) or lumen areas (11.64 Ϯ 5.7 mm 2 and 13.2 Ϯ 2.6 mm 2 ) between control and PAE cell implants, respectively, suggesting that most of the benefits were localized to the native vessel. At 4 weeks after implant, there was minimal stenosis and luminal occlusion observed at the arterial sites and no obvious differences in vessel remodeling between groups (data not shown).
Minimal inflammation was present in the adventitia of the venous implant sites in animals from both groups at days 3 and 28, with no significant differences between control anastomoses and those treated with PAE cells (Table II) . Fibrosis was also present in the adventitia of veins in animals from both groups at 3 and 28 days, with an increase in fibrosis at 1 month consistent with the healing process. Less fibrosis was noted in veins treated with PAE cells compared with veins in control animals at 28 days (Table II) .
Evidence of neovascularization was also observed in both groups at both time points. Both acute and chronic neovascularization was decreased in veins treated with PAE cells compared with control (Table II, Fig 3) . No significant circumferential variation was seen in any of the sections analyzed for histomorphology or histopathology. Noneto-minimal luminal inflammation was observed at 3 and 28 days in this model, and no difference was observed between groups (data not shown).
Matrix metalloproteinase localization. Immunohistochemical analysis of MMP expression in the total vessel, intima, media and adventitia 3 and 28 days after surgery revealed reduced expression in veins treated with PAE cells compared with control veins, with most of the positive staining localized to the extracellular matrix. In the control group, significant MMP-2 staining was observed in the adventitia, media, and intima at day 3 (11.2% Ϯ 1.0%, 4.4% Ϯ 0.6% and 2.1% Ϯ 0.2%, respectively), with most of the staining located in the adventitia (Fig 4) . Decreased expression of MMP-2 was observed in the adventitia, media, and intima of vessels treated with PAE cells at day 3 (6.9% Ϯ 1.2%, 2.3% Ϯ 0.4%, and 0.8% Ϯ 0.2%, respectively, P Ͻ .05). At 28 days, the amount of staining had decreased in the adventitia (5.7% Ϯ 0.9%) of control veins, but the staining in the media and intima were still significantly increased (4.9% Ϯ 1.0% and 2.6% Ϯ 0.8%, respectively) compared with veins treated with PAE cells (1.3% Ϯ 0.2% and 0.3% Ϯ 0.1%, respectively, P Ͻ .05). A strong negative correlation was observed between total MMP-2 expression and lumen diameter at 28 days (r ϭ -0.80, P Ͻ .009; Fig 4) .
MMP-9 staining was less intense in both the control and treated groups at both time points compared with MMP-2 staining (Appendix Fig, online only) . At 3 days there was reduced staining in the adventitia of veins treated with PAE cells compared with the control (P Ͻ .05). At 28 days, decreased MMP-9 expression was observed in the intima and adventitia of the treated group compared with control (P Ͻ .05).
DISCUSSION
The major findings in this study are that the adventitial application of endothelial implants significantly reduced MMP-2 expression within the venous wall at 3 days and increased venous lumen diameter and positive remodeling at 28 days in porcine AVGs compared with control. The data presented here provide further information on the mechanism of action of the perivascular implants and AVG failure. Positive remodeling is an important factor in the success or failure of an AVG because the vein must accommodate arterial blood flow and pressure. Lumen diameter is the functional parameter used in vascular clinical trials and is not only determined by the degree of intimal thickening but is also influenced by the overall change in vessel size due to remodeling of the vessel wall. Therefore, in this study we examined the role of perivascular PAE cells on venous lumen size, remodeling, and vein-graft stenosis.
The mechanism of graft failure is a complex, multifactorial pathologic process that involves a combination of many biologic events, and it is therefore unlikely that a single agent aimed at any one process could prove successful in treating the cause of AVG failure. This is indeed the case, because despite success in animal models of AVG stenosis, [15] [16] [17] [18] approaches to reduce clinical graft failure have thus far proven unsuccessful. 4 The endothelial cell implants described here represent a novel approach to addressing this problem. In addition to increasing venous lumen and vessel area and decreasing vascular stenosis, cell-containing implants also inhibited adventitial fibrosis at 28 days and neovascularization at 3 days and 28 days.
In recent years, the adventitia has emerged as a key regulator of vascular remodeling. 19 The adventitia consists primarily of fibroblasts, which proliferate and migrate toward the intima after vessel injury. 8, 20 An increase in adventitial fibrosis may constrict the injured vessel and contribute to vascular remodeling and lumen loss. 21 MMPs are necessary for the migration of adventitial and medial cells into the neointima after vascular injury by degrading extracellular matrix proteins. 22 The upregulation of MMP-2 and MMP-9 and down regulation of their inhibitors, TIMPs, coincide with the formation of neointima and remodeling after vascular injury. [23] [24] [25] Indeed, it has been shown that adventitial expression of MMP-2 increases after vascular injury in porcine AVGs. 26 In the present study, MMP-2 expression was reduced in veins treated with PAE cells compared with control veins. Most MMP-2 activity was localized to the adventitia at day 3 and to the intima and media at 1 month. This is in agreement with previous studies suggesting that increased MMP activity may be necessary for cell migration to the intima to occur. 18, 26 MMP-2 expression in the venous wall correlated strongly with a decrease in lumen diameter at 28 days, suggesting that a potential mode of action of the perivascular endothelial implants in this model may be to modulate MMP-2 activity.
MMP proteolysis is also a critical component of neovascularization, 27 which has been implicated in the formation of stenosis and luminal narrowing. 9, 28 In particular, MMP-2 plays an essential role in extracellular matrix- induced angiogenesis. 29 In the present study, adventitial neovascularization was reduced in veins treated with implants containing PAE cells compared with control veins. Although adventitial inflammation has also been correlated with negative vascular remodeling, 7 minimal perivascular inflammation was noted in this study with no significant differences between groups. The absence of significant adventitial and luminal inflammation may have been due to the use of dexamethasone in this model.
Confluent endothelial cells release a variety of biologic agents that in combination inhibit cell migration, proliferation, and intimal thickening. [30] [31] [32] The benefit of using perivascular implants compared with a single agent is the ability to theoretically target multiple biologic responses to injury rather than a single event:
• HS secreted by endothelial cells is a potent inhibitor of SMC proliferation and migration as well as platelet activation, adhesion, and thrombus formation. 33, 34 • TGF-␤ 1 inhibits SMC and fibroblast proliferation and regulates the expression of MMPs. 35, 36 • TIMP-2 can form a tight 1:1 inhibitory complex with MMP-2, but TIMP-2 is also known to inhibit cell growth and angiogenesis. 23, 27, 37 • Endothelial-derived NO is a potent vasodilator with many functions within the vessel wall and its response to injury. 32, 38 NO has been shown to decrease MMP-2 and MMP-9 activities and increased TIMP secretion. 39 The lack of circumferential variation in the histopathologic analysis of venous tissue suggests that the effects of the implants or their factors, or both, are distributed circumferentially throughout the blood vessel wall. The effects rendered by the implants were determined to be due to the presence of cells because sham matrices produced no benefit. In previous porcine vascular injury models, we have shown the presence of confluent endothelial cells within the implants 3 days after implantation. 13 By 28-days, although cells can be found in the implant, there is substantial cell loss that is partly due to in vivo degradation of the gelatin matrix. 11 However, the data presented here and supported by previous studies indicate that the endothelial implants, or factors secreted by the cells, may provide control over the response to injury by influencing early events such as MMP expression and neovascularization.
A limitation of the present study was that zymography was not used, and therefore, the levels of active vs latent MMP could not be assessed. Follow-up studies are needed to address this issue. The animals used in this study were young, healthy, and not uremic, and their grafts were not accessed during the time course of the study; therefore, the impact of additional risk factors associated with hemodialysis patients were not assessed. However, the data presented here suggest that adventitial endothelial cell implants may be useful in decreasing luminal narrowing in a clinical setting. Indeed, arteriovenous graft and fistula trials investigating endothelial implants in hemodialysis patients are currently ongoing.
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